Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Connor Willis, David A. Sallman, Malinda Tan, Madeline Brendle, Vonetta L. Williams, Craig Comperatore, Trang Au, Srinivas K. Tantravahi, Najla Al Ali, Jeffrey A. Gilreath, Tibor Kovacsovics, Xiting Cao, Islam Sadek, Rami S. Komrokji, David Stenehjem

Blood (2022) 140 (Supplement 1): 5291–5292.

https://doi.org/10.1182/blood-2022-162622

Published: 2022

Journal Articles

Clinical Characteristics and Late-Line Treatment Patterns of Patients with Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices

Pareshkumar Patel, Aditya Raju, Anna Coutinho, Rodrigo Maegawa, Orsolya Lunacsek, Kathryn Deyoung, Serban Iorga, Xiting Cao

Blood (2021) 138 (Supplement 1): 5036.

https://doi.org/10.1182/blood-2021-152619

Published: 2021

Journal Articles

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Sudipto Mukherjee, MD PhD MPH, Xiting Cao, Islam Sadek, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Irina Pivneva, Annie Guérin, B. Douglas Smith, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-137079

Published: 2020

Journal Articles

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Ehab L. Atallah, MD, Islam Sadek, Xiting Cao, Dominick Latremouille-Viau, Irina Pivneva, PhD, Carmine Rossi, Annie Guerin, Vamsi Kota, MBBS

Blood (2019) 134 (Supplement_1): 2208.

https://doi.org/10.1182/blood-2019-125736

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Eytan M. Stein, MD, Dominick Latremouille-Viau, George J Joseph, Sherry Shi, Annie Guerin, MSc, Eric Q Wu, Gaetano Bonifacio, Xiting Cao

Blood (2019) 134 (Supplement_1): 3495.

https://doi.org/10.1182/blood-2019-124878

Published: 2019

Journal Articles

Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/ Refractory Multiple Myeloma (rrMM) Patients

Changxia Shao, PhD, Matthew Monberg, PhD, Xiting Cao, PhD, Wei Zhou, PhD, Yichen Zhong, MHS, Patricia Marinello, PharmD

Blood (2016) 128 (22): 3555.

https://doi.org/10.1182/blood.V128.22.3555.3555

Published: 2016

Journal Articles

Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)

Changxia Shao, PhD, Jinan Liu, PhD, Wei Zhou, PhD, Monika Kumar Raut, PhD, Matthew Monberg, PhD, Xiting Cao, PhD, Alejandro Daniel Ricart, MD, Arun Balakumaran, MD PhD SM

Blood (2016) 128 (22): 2377.

https://doi.org/10.1182/blood.V128.22.2377.2377

Published: 2016

NARROW

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Clinical Characteristics and Late-Line Treatment Patterns of Patients with Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/ Refractory Multiple Myeloma (rrMM) Patients

Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)

Email alerts

ASH Publications

American Society of Hematology

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Clinical Characteristics and Late-Line Treatment Patterns of Patients with Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Tyrosine Kinase Inhibitor Therapy Discontinuation in Clinical Practice in Chronic Myeloid Leukemia - a US Physician Survey Conducted after Guideline Updates

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/ Refractory Multiple Myeloma (rrMM) Patients

Utilization Patterns and Resource Use in Relapse/Refractory Hodgkin Lymphoma (rrHL) Patients Treated with Brentuximab Vedotin (BV)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only